Novel mechanisms and functions of complement

Nature Immunology

Volumn 18, Issue 12, 2017, Pages 1288-1298

  Hajishengallis, George ^a   Reis, Edimara S ^b   Mastellos, Dimitrios C ^c   Ricklin, Daniel ^d   Lambris, John D ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

^d UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C3D; COMPLEMENT COMPONENT C5; COMPLEMENT RECEPTOR; G PROTEIN COUPLED RECEPTOR; COMPLEMENT;

AGE RELATED MACULAR DEGENERATION; AGING; ALZHEIMER DISEASE; CHRONIC INFLAMMATION; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; DEGENERATIVE DISEASE; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOREGULATION; INFECTION; INFLAMMATORY DISEASE; MALIGNANT NEOPLASM; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW; CD4+ T LYMPHOCYTE; HOMEOSTASIS; IMMUNOLOGY; INFLAMMATION; INNATE IMMUNITY; METABOLISM; NEOPLASM;

CD4-POSITIVE T-LYMPHOCYTES; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; HOMEOSTASIS; HUMANS; IMMUNITY, INNATE; INFLAMMATION; NEOPLASMS;

EID: 85034570767     PISSN: 15292908     EISSN: 15292916     Source Type: Journal    
DOI: 10.1038/ni.3858     Document Type: Review

References (128)

1. Ricklin, D., Hajishengallis, G., Yang, K. &Lambris, J.D. Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 11, 785-797 (2010).
2. Arbore, G., Kemper, C. &Kolev, M. Intracellular complement-the complosome-in immune cell regulation. Mol. Immunol. 89, 2-9 (2017).
3. Ricklin, D., Reis, E.S. &Lambris, J.D. Complement in disease: a defence system turning offensive. Nat. Rev. Nephrol. 12, 383-401 (2016).
4. Elmlund, D., Le, S.N. &Elmlund, H. High-resolution cryo-EM: the nuts and bolts. Curr. Opin. Struct. Biol. 46, 1-6 (2017).
5. Ricklin, D., Reis, E.S., Mastellos, D.C., Gros, P. &Lambris, J.D. Complement component C3-The "Swiss Army Knife" of innate immunity and host defense. Immunol. Rev. 274, 33-58 (2016).
6. Schatz-Jakobsen, J.A., Pedersen, D.V. &Andersen, G.R. Structural insight into proteolytic activation and regulation of the complement system. Immunol. Rev. 274, 59-73 (2016).
7. Liszewski, M.K., Elvington, M., Kulkarni, H.S. &Atkinson, J.P. Complement's hidden arsenal: new insights and novel functions inside the cell. Mol. Immunol. 84, 2-9 (2017).
8. Hajishengallis, G. &Lambris, J.D. More than complementing Tolls: complement-Toll-like receptor synergy and crosstalk in innate immunity and inflammation. Immunol. Rev. 274, 233-244 (2016).
9. Hovingh, E.S., van den Broek, B. &Jongerius, I. Hijacking complement regulatory proteins for bacterial immune evasion. Front. Microbiol. 7, 2004 (2016).
10. Dempsey, P.W., Allison, M.E., Akkaraju, S., Goodnow, C.C. &Fearon, D.T. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 271, 348-350 (1996).
11. Kaya, Z. et al. Contribution of the innate immune system to autoimmune myocarditis: a role for complement. Nat. Immunol. 2, 739-745 (2001).
12. Strainic, M.G. et al. Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+ T cells. Immunity 28, 425-435 (2008).
13. Liszewski, M.K. et al. Intracellular complement activation sustains T cell homeostasis and mediates effector differentiation. Immunity 39, 1143-1157 (2013).
14. Arbore, G. et al. T helper 1 immunity requires complement-driven NLRP3 inflammasome activity in CD4+ T cells. Science 352, aad1210 (2016).
15. Lambris, J.D., Dobson, N.J. &Ross, G.D. Release of endogenous C3b inactivator from lymphocytes in response to triggering membrane receptors for beta 1H globulin. J. Exp. Med. 152, 1625-1644 (1980).
16. Sundsmo, J.S. The leukocyte complement system. Fed. Proc. 41, 3094-3098 (1982).
17. Freeley, S., Kemper, C. &Le Friec, G. The "ins and outs" of complement-driven immune responses. Immunol. Rev. 274, 16-32 (2016).
18. Elvington, M., Liszewski, M.K., Bertram, P., Kulkarni, H.S. &Atkinson, J.P.A. A C3(H20) recycling pathway is a component of the intracellular complement system. J. Clin. Invest. 127, 970-981 (2017).
19. Kolev, M. &Kemper, C. Keeping it all going-complement meets metabolism. Front. Immunol. 8, 1 (2017).
20. Kolev, M. et al. Complement regulates nutrient influx and metabolic reprogramming during Th1 cell responses. Immunity 42, 1033-1047 (2015).
21. Cardone, J. et al. Complement regulator CD46 temporally regulates cytokine production by conventional and unconventional T cells. Nat. Immunol. 11, 862-871 (2010).
22. Acosta-Rodriguez, E.V., Napolitani, G., Lanzavecchia, A. &Sallusto, F. Interleukins 1β and 6 but not transforming growth factor-β are essential for the differentiation of interleukin 17-producing human T helper cells. Nat. Immunol. 8, 942-949 (2007).
23. Khameneh, H.J. et al. C5a regulates IL-1β production and leukocyte recruitment in a murine model of monosodium urate crystal-induced peritonitis. Front. Pharmacol. 8, 10 (2017).
24. Asgari, E. et al. C3a modulates IL-1β secretion in human monocytes by regulating ATP efflux and subsequent NLRP3 inflammasome activation. Blood 122, 3473-3481 (2013).
25. Triantafilou, K., Hughes, T.R., Triantafilou, M. &Morgan, B.P. The complement membrane attack complex triggers intracellular Ca2+ fluxes leading to NLRP3 inflammasome activation. J. Cell Sci. 126, 2903-2913 (2013).
26. Laudisi, F. et al. Cutting edge: the NLRP3 inflammasome links complement-mediated inflammation and IL-1β release. J. Immunol. 191, 1006-1010 (2013).
27. Gurcel, L., Abrami, L., Girardin, S., Tschopp, J. &van der Goot, F.G. Caspase-1 activation of lipid metabolic pathways in response to bacterial pore-forming toxins promotes cell survival. Cell 126, 1135-1145 (2006).
28. Benoit, M.E., Clarke, E.V., Morgado, P., Fraser, D.A. &Tenner, A.J. Complement protein C1q directs macrophage polarization and limits inflammasome activity during the uptake of apoptotic cells. J. Immunol. 188, 5682-5693 (2012).
29. Levy, M., Kolodziejczyk, A.A., Thaiss, C.A. &Elinav, E. Dysbiosis and the immune system. Nat. Rev. Immunol. 17, 219-232 (2017).
30. Hajishengallis, G., Abe, T., Maekawa, T., Hajishengallis, E. &Lambris, J.D. Role of complement in host-microbe homeostasis of the periodontium. Semin. Immunol. 25, 65-72 (2013).
31. Hajishengallis, G. Immunomicrobial pathogenesis of periodontitis: keystones, pathobionts, and host response. Trends Immunol. 35, 3-11 (2014).
32. Hasegawa, M. et al. Interleukin-22 regulates the complement system to promote resistance against pathobionts after pathogen-induced intestinal damage. Immunity 41, 620-632 (2014).
33. Chehoud, C. et al. Complement modulates the cutaneous microbiome and inflammatory milieu. Proc. Natl. Acad. Sci. USA 110, 15061-15066 (2013).
34. Wang, H.-B., Ricklin, D. &Lambris, J.D. Complement activation fragment C4a, a novel untethered agonist, mediates effector functions by binding to PAR1 and PAR4. Proc. Natl. Acad. Sci. USA (in the press).
35. Ekdahl, K.N. et al. Dangerous liaisons: complement, coagulation, and kallikrein/kinin cross-talk act as a linchpin in the events leading to thromboinflammation. Immunol. Rev. 274, 245-269 (2016).
36. Riewald, M., Petrovan, R.J., Donner, A., Mueller, B.M. &Ruf, W. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 296, 1880-1882 (2002).
37. Schonthaler, H.B. et al. S100A8-S100A9 protein complex mediates psoriasis by regulating the expression of complement factor C3. Immunity 39, 1171-1181 (2013).
38. Rafail, S. et al. Complement deficiency promotes cutaneous wound healing in mice. J. Immunol. 194, 1285-1291 (2015).
39. Winter, S.E. &Bäumler, A.J. Dysbiosis in the inflamed intestine: chance favors the prepared microbe. Gut Microbes 5, 71-73 (2014).
40. Hajishengallis, G. Periodontitis: from microbial immune subversion to systemic inflammation. Nat. Rev. Immunol. 15, 30-44 (2015).
41. Maekawa, T. et al. Porphyromonas gingivalis manipulates complement and TLR signaling to uncouple bacterial clearance from inflammation and promote dysbiosis. Cell Host Microbe 15, 768-778 (2014).
42. Hajishengallis, G. et al. Low-abundance biofilm species orchestrates inflammatory periodontal disease through the commensal microbiota and complement. Cell Host Microbe 10, 497-506 (2011).
43. Tam, J.C., Bidgood, S.R., McEwan, W.A. &James, L.C. Intracellular sensing of complement C3 activates cell autonomous immunity. Science 345, 1256070 (2014).
44. Helmy, K.Y. et al. CRIg: a macrophage complement receptor required for phagocytosis of circulating pathogens. Cell 124, 915-927 (2006).
45. Zeng, Z. et al. CRIg functions as a macrophage pattern recognition receptor to directly bind and capture blood-borne gram-positive bacteria. Cell Host Microbe 20, 99-106 (2016).
46. Kim, K.H. et al. Extracellular stimulation of VSIG4/complement receptor Ig suppresses intracellular bacterial infection by inducing autophagy. Autophagy 12, 1647-1659 (2016).
47. Mosser, D.M. &Edelson, P.J. The third component of complement (C3) is responsible for the intracellular survival of Leishmania major. Nature 327, 329-331 (1987).
48. Dai, S., Rajaram, M.V., Curry, H.M., Leander, R. &Schlesinger, L.S. Fine tuning inflammation at the front door: macrophage complement receptor 3-mediates phagocytosis and immune suppression for Francisella tularensis. PLoS Pathog. 9, e1003114 (2013).
49. Lambris, J.D., Ricklin, D. &Geisbrecht, B.V. Complement evasion by human pathogens. Nat. Rev. Microbiol. 6, 132-142 (2008).
50. Bennett, K.M., Rooijakkers, S.H.M. &Gorham, R.D. Jr. Let's tie the knot: marriage of complement and adaptive immunity in pathogen evasion, for better or worse. Front. Microbiol. 8, 89 (2017).
51. Ricklin, D. &Lambris, J.D. Complement in immune and inflammatory disorders: pathophysiological mechanisms. J. Immunol. 190, 3831-3838 (2013).
52. Shaw, A.C., Goldstein, D.R. &Montgomery, R.R. Age-dependent dysregulation of innate immunity. Nat. Rev. Immunol. 13, 875-887 (2013).
53. van Lookeren Campagne, M., Strauss, E.C. &Yaspan, B.L. Age-related macular degeneration: complement in action. Immunobiology 221, 733-739 (2016).
54. Brennan, F.H., Lee, J.D., Ruitenberg, M.J. &Woodruff, T.M. Therapeutic targeting of complement to modify disease course and improve outcomes in neurological conditions. Semin. Immunol. 28, 292-308 (2016).
55. Thurman, J.M. Complement in kidney disease: core curriculum 2015. Am. J. Kidney Dis. 65, 156-168 (2015).
56. Stephan, A.H., Barres, B.A. &Stevens, B. The complement system: an unexpected role in synaptic pruning during development and disease. Annu. Rev. Neurosci. 35, 369-389 (2012).
57. Liddelow, S.A. et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature 541, 481-487 (2017).
58. Hawksworth, O.A., Coulthard, L.G. &Woodruff, T.M. Complement in the fundamental processes of the cell. Mol. Immunol. 84, 17-25 (2017).
59. Stevens, B. et al. The classical complement cascade mediates CNS synapse elimination. Cell 131, 1164-1178 (2007).
60. Schafer, D.P. et al. Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron 74, 691-705 (2012).
61. Bialas, A.R. &Stevens, B. TGF-β signaling regulates neuronal C1q expression and developmental synaptic refinement. Nat. Neurosci. 16, 1773-1782 (2013).
62. Howell, G.R. et al. Molecular clustering identifies complement and endothelin induction as early events in a mouse model of glaucoma. J. Clin. Invest. 121, 1429-1444 (2011).
63. Shi, Q. et al. Complement C3-deficient mice fail to display age-related hippocampal decline. J. Neurosci. 35, 13029-13042 (2015).
64. Whalley, K. Neurodegenerative disease: complement mediates pathological pruning. Nat. Rev. Neurosci. 17, 336 (2016).
65. Vasek, M.J. et al. A complement-microglial axis drives synapse loss during virus-induced memory impairment. Nature 534, 538-543 (2016).
66. Wyatt, S.K., Witt, T., Barbaro, N.M., Cohen-Gadol, A.A. &Brewster, A.L. Enhanced classical complement pathway activation and altered phagocytosis signaling molecules in human epilepsy. Exp. Neurol. 295, 184-193 (2017).
67. Heppner, F.L., Ransohoff, R.M. &Becher, B. Immune attack: the role of inflammation in Alzheimer disease. Nat. Rev. Neurosci. 16, 358-372 (2015).
68. Veerhuis, R., Nielsen, H.M. &Tenner, A.J. Complement in the brain. Mol. Immunol. 48, 1592-1603 (2011).
69. Ager, R.R. et al. Microglial C5aR (CD88) expression correlates with amyloid-beta deposition in murine models of Alzheimer's disease. J. Neurochem. 113, 389-401 (2010).
70. Fonseca, M.I. et al. Treatment with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer's disease. J. Immunol. 183, 1375-1383 (2009).
71. Hong, S. et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science 352, 712-716 (2016).
72. Shi, Q. et al. Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice. Sci. Transl. Med. 9, eaaf6295 (2017).
73. Liu, H. et al. Augmented Wnt signaling in a mammalian model of accelerated aging. Science 317, 803-806 (2007).
74. Naito, A.T. et al. Complement C1q activates canonical Wnt signaling and promotes aging-related phenotypes. Cell 149, 1298-1313 (2012).
75. Clevers, H. Wnt/β-catenin signaling in development and disease. Cell 127, 469-480 (2006).
76. Sumida, T. et al. Complement C1q-induced activation of β-catenin signalling causes hypertensive arterial remodelling. Nat. Commun. 6, 6241 (2015).
77. Castellano, G. et al. Complement modulation of anti-aging factor klotho in ischemia/reperfusion injury and delayed graft function. Am. J. Transplant. 16, 325-333 (2016).
78. Hageman, G.S. et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc. Natl. Acad. Sci. USA 102, 7227-7232 (2005).
79. Haines, J.L. et al. Complement factor H variant increases the risk of age-related macular degeneration. Science 308, 419-421 (2005).
80. Calippe, B. et al. Complement factor H inhibits CD47-mediated resolution of inflammation. Immunity 46, 261-272 (2017).
81. Wang, Q. et al. Identification of a central role for complement in osteoarthritis. Nat. Med. 17, 1674-1679 (2011).
82. Maekawa, T. et al. Genetic and intervention studies implicating complement C3 as a major target for the treatment of periodontitis. J. Immunol. 192, 6020-6027 (2014).
83. Maekawa, T. et al. Inhibition of pre-existing natural periodontitis in non-human primates by a locally administered peptide inhibitor of complement C3. J. Clin. Periodontol. 43, 238-249 (2016).
84. Pandey, M.K. et al. Complement drives glucosylceramide accumulation and tissue inflammation in Gaucher disease. Nature 543, 108-112 (2017).
85. Trinchieri, G. Cancer and inflammation: an old intuition with rapidly evolving new concepts. Annu. Rev. Immunol. 30, 677-706 (2012).
86. Balkwill, F.R. &Mantovani, A. Cancer-related inflammation: common themes and therapeutic opportunities. Semin. Cancer Biol. 22, 33-40 (2012).
87. Hanahan, D. &Weinberg, R.A. Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011).
88. Hajishengallis, G. et al. Complement inhibition in pre-clinical models of periodontitis and prospects for clinical application. Semin. Immunol. 28, 285-291 (2016).
89. Kemper, C. &Köhl, J. Novel roles for complement receptors in T cell regulation and beyond. Mol. Immunol. 56, 181-190 (2013).
90. Reis, E.S., Mastellos, D.C., Ricklin, D., Mantovani, A. &Lambris, J.D. Complement in cancer: untangling an intricate relationship. Nat. Rev. Immunol. (in the press).
91. Hsieh, C.C. et al. The role of complement component 3 (C3) in differentiation of myeloid-derived suppressor cells. Blood 121, 1760-1768 (2013).
92. Markiewski, M.M. et al. Modulation of the antitumor immune response by complement. Nat. Immunol. 9, 1225-1235 (2008).
93. Corrales, L. et al. Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression. J. Immunol. 189, 4674-4683 (2012).
94. Doerner, S.K. et al. High-fat diet-induced complement activation mediates intestinal inflammation and neoplasia, independent of obesity. Mol. Cancer Res. 14, 953-965 (2016).
95. Guglietta, S. et al. Coagulation induced by C3aR-dependent NETosis drives protumorigenic neutrophils during small intestinal tumorigenesis. Nat. Commun. 7, 11037 (2016).
96. Nabizadeh, J.A. et al. The complement C3a receptor contributes to melanoma tumorigenesis by inhibiting neutrophil and CD4+ T cell responses. J. Immunol. 196, 4783-4792 (2016).
97. Ning, C. et al. Complement activation promotes colitis-associated carcinogenesis through activating intestinal IL-1β/IL-17A axis. Mucosal Immunol. 8, 1275-1284 (2015).
98. Vadrevu, S.K. et al. Complement c5a receptor facilitates cancer metastasis by altering T-cell responses in the metastatic niche. Cancer Res. 74, 3454-3465 (2014).
99. Bonavita, E. et al. PTX3 is an extrinsic oncosuppressor regulating complement-dependent inflammation in cancer. Cell 160, 700-714 (2015).
100. Ajona, D. et al. A combined PD-1/C5a Blockade synergistically protects against lung cancer growth and metastasis. Cancer Discov. 7, 694-703 (2017).
101. Bulla, R. et al. C1q acts in the tumour microenvironment as a cancer-promoting factor independently of complement activation. Nat. Commun. 7, 10346 (2016).
102. Ajona, D. et al. Investigation of complement activation product c4d as a diagnostic and prognostic biomarker for lung cancer. J. Natl. Cancer Inst. 105, 1385-1393 (2013).
103. Nunez-Cruz, S. et al. Genetic and pharmacologic inhibition of complement impairs endothelial cell function and ablates ovarian cancer neovascularization. Neoplasia 14, 994-1004 (2012).
104. Kaida, T. et al. C5a receptor (CD88) promotes motility and invasiveness of gastric cancer by activating RhoA. Oncotarget 7, 84798-84809 (2016).
105. Abdelbaset-Ismail, A. et al. Activation of the complement cascade enhances motility of leukemic cells by downregulating expression of HO-1. Leukemia 31, 446-458 (2017).
106. Han, X., Zha, H., Yang, F., Guo, B. &Zhu, B. Tumor-derived tissue factor aberrantly activates complement and facilitates lung tumor progression via recruitment of myeloid-derived suppressor cells. Int. J. Mol. Sci. 18, 22 10.3390/ijms18010022 (2017).
107. Boire, A. et al. Complement component 3 adapts the cerebrospinal fluid for leptomeningeal metastasis. Cell 168, 1101-1113 e13 (2017).
108. Cho, M.S. et al. Complement component 3 is regulated by TWIST1 and mediates epithelial-mesenchymal transition. j. immunol. 196, 1412-1418 (2016).
109. Towner, L.D., Wheat, R.A., Hughes, T.R. &Morgan, B.P. Complement membrane attack and tumorigenesis: a systems biology approach. J. Biol. Chem. 291, 14927-14938 (2016).
110. Wang, Y. et al. Autocrine complement inhibits IL10-dependent T-cell-mediated antitumor immunity to promote tumor progression. Cancer Discov. 6, 1022-1035 (2016).
111. Surace, L. et al. Complement is a central mediator of radiotherapy-induced tumor-specific immunity and clinical response. Immunity 42, 767-777 (2015).
112. Taylor, R.P. &Lindorfer, M.A. Cytotoxic mechanisms of immunotherapy: harnessing complement in the action of anti-tumor monoclonal antibodies. Semin. Immunol. 28, 309-316 (2016).
113. Gunn, L. et al. Opposing roles for complement component C5a in tumor progression and the tumor microenvironment. J. Immunol. 189, 2985-2994 (2012).
114. Facciabene, A. et al. Local endothelial complement activation reverses endothelial quiescence, enabling t-cell homing, and tumor control during t-cell immunotherapy. OncoImmunology 6, e1326442 (2017).
115. Diebolder, C.A. et al. Complement is activated by IgG hexamers assembled at the cell surface. Science 343, 1260-1263 (2014).
116. de Jong, R.N. et al. A novel platform for the potentiation of therapeutic antibodies based on antigen-dependent formation of IgG hexamers at the cell surface. PLoS Biol. 14, e1002344 (2016).
117. Cook, E.M. et al. Antibodies that efficiently form hexamers upon antigen binding can induce complement-dependent cytotoxicity under complement-limiting conditions. J. Immunol. 197, 1762-1775 (2016).
118. Forneris, F. et al. Structures of C3b in complex with factors B and D give insight into complement convertase formation. Science 330, 1816-1820 (2010).
119. Katschke, K.J. Jr. et al. Inhibiting alternative pathway complement activation by targeting the factor D exosite. J. Biol. Chem. 287, 12886-12892 (2012).
120. Mastellos, D.C. et al. Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention. Eur. J. Clin. Invest. 45, 423-440 (2015).
121. Forneris, F. et al. Regulators of complement activity mediate inhibitory mechanisms through a common C3b-binding mode. EMBO J. 35, 1133-1149 (2016).
122. Roversi, P. et al. Structural basis for complement factor I control and its disease-associated sequence polymorphisms. Proc. Natl. Acad. Sci. USA 108, 12839-12844 (2011).
123. Xue, X. et al. Regulator-dependent mechanisms of C3b processing by factor I allow differentiation of immune responses. Nat. Struct. Mol. Biol. 24, 643-651 (2017).
124. Wu, J. et al. Structure of complement fragment C3b-factor H and implications for host protection by complement regulators. Nat. Immunol. 10, 728-733 (2009).
125. Papanastasiou, M. et al. Structural implications for the formation and function of the complement effector protein iC3b. J. Immunol. 198, 3326-3335 (2017).
126. van den Elsen, J.M. &Isenman, D.E. A crystal structure of the complex between human complement receptor 2 and its ligand C3d. Science 332, 608-611 (2011).
127. Xu, S., Wang, J., Wang, J.H. &Springer, T.A. Distinct recognition of complement iC3b by integrins αXβ2 and αMβ2. Proc. Natl. Acad. Sci. USA 114, 3403-3408 (2017).
128. Bajic, G., Yatime, L., Sim, R.B., Vorup-Jensen, T. &Andersen, G.R. Structural insight on the recognition of surface-bound opsonins by the integrin I domain of complement receptor 3. Proc. Natl. Acad. Sci. USA 110, 16426-16431 (2013).